Company news
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) news
Tarsus Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 29, 2026: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex…
Press releases & updates
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
September 28, 2026
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
September 4, 2026
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
August 6, 2026
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
August 6, 2026
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
August 6, 2026
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
August 4, 2026
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
July 13, 2026
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
July 8, 2026
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
May 6, 2026
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 29, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05, a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
April 1, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 30, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
March 22, 2026
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
February 23, 2026
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
February 18, 2026
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
February 17, 2026
Tarsus to Participate in Upcoming Investor Conference
November 23, 2025
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
November 3, 2025
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 27, 2025
Tarsus to Participate in Upcoming Investor Conferences
August 26, 2025
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
August 5, 2025
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
July 29, 2025
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
April 30, 2025
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
April 23, 2025
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
April 21, 2025
Tarsus Announces Proposed $100.0 Million Public Offering
March 11, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
March 11, 2025
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements
February 24, 2025
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
February 19, 2025
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
January 12, 2025
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
November 12, 2024
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
November 12, 2024
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
November 5, 2024
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
November 4, 2024
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
October 16, 2024
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
September 24, 2024
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
August 27, 2024
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
August 7, 2024
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 28, 2024
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 8, 2024
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 7, 2024
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
April 30, 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 22, 2024
Tarsus to Participate at Upcoming Investor Conferences
March 4, 2024
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 4, 2024
Tarsus Announces Pricing of $100.0 Million Public Offering
February 29, 2024
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
February 26, 2024
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 21, 2024
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
February 19, 2024
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
January 30, 2024